Pašalić Daria, Pauković Paulina, Cvijetić Selma, Pizent Alica, Jurasović Jasna, Milković-Kraus Sanja, Dodig Slavica, Mück-Šeler Dorotea, Mustapić Maja, Pivac Nela, Pavlović Mladen
Department of Chemistry, Biochemistry, and Clinical Chemistry, School of Medicine, University of Zagreb, Zagreb, Croatia.
Genet Test Mol Biomarkers. 2012 Jun;16(6):598-604. doi: 10.1089/gtmb.2011.0279. Epub 2012 Mar 15.
The aim of this study was to determine the relationship between body mass index, biochemical parameters, and 5-hydroxytryptamine (5-HT) genetic polymorphisms and prostate dysfunction in an elderly general male population.
One hundred and seventeen elderly male subjects [60 men without symptoms of prostate hyperplasia, 42 men with untreated benign prostatic hyperplasia (BPH), and 15 men with prostate cancer (PCa)] treated with finasteride or flutamide were included. Multiple comparisons showed significant difference in age, T-score, concentration of phosphorus, calcium, C-reactive protein, and prostate-specific antigen (PSA) between the groups. T-score was the lowest and phosphorus concentration was the highest in the PCa group. Highest PSA, proteins, calcium, and Hekal's formula score were found in the BPH group. Patients with PCa were more frequent GG+GA carriers of 5-HT1B 1997A/G gene polymorphism (p=0.035). Univariate regression analysis showed association of PCa-treated subjects with age (p=0.010) and 5-HT1B genetic polymorphism (p=0.018). Antiandrogen therapy affects T-score (p=0.017), serum phosphorus (p=0.008), glucose (p=0.036), and total proteins (p=0.050). Multivariate-stepwise logistic regression analysis showed the significant association of treated PCa with age (p=0.028) and inorganic phosphorus (p=0.005), and a marginal association with ultrasonographic T-score (p=0.052).
Antiandrogen therapy might induce bone mineral loss in elderly PCa patients. Preliminary data imply that the genetic variants of the 5-HT1B receptor might be associated with PCa.
本研究旨在确定老年男性普通人群中体重指数、生化参数、5-羟色胺（5-HT）基因多态性与前列腺功能障碍之间的关系。
纳入了117名接受非那雄胺或氟他胺治疗的老年男性受试者[60名无前列腺增生症状的男性、42名未经治疗的良性前列腺增生（BPH）男性和15名前列腺癌（PCa）男性]。多重比较显示，各组之间在年龄、T值、磷、钙、C反应蛋白和前列腺特异性抗原（PSA）浓度方面存在显著差异。PCa组的T值最低，磷浓度最高。BPH组的PSA、蛋白质、钙和Hekal公式评分最高。PCa患者中5-HT1B 1997A/G基因多态性的GG+GA携带者更为常见（p=0.035）。单因素回归分析显示，接受PCa治疗的受试者与年龄（p=0.010）和5-HT1B基因多态性（p=0.018）有关。抗雄激素治疗会影响T值（p=0.017）、血清磷（p=0.008）、葡萄糖（p=0.036）和总蛋白（p=0.050）。多因素逐步逻辑回归分析显示，接受治疗的PCa与年龄（p=0.028）和无机磷（p=0.005）显著相关，与超声T值有边缘相关性（p=0.052）。
抗雄激素治疗可能会导致老年PCa患者出现骨矿物质流失。初步数据表明，5-HT1B受体的基因变异可能与PCa有关。
